Even in schizophrenia cases lacking intellectual disability, investigators found that rare mutations in genes normally resistant to loss-of-function changes were enriched.
Members of the ProfiLER trial identified actionable mutations in more than half of individuals with advanced cancers, though only a fraction received targeted therapy.
Researchers are developing new algorithms and using machine-learning techniques that can integrate vast amounts of cancer omics data to identify potential therapies.
Shared gastric adenocarcinoma tumor features seem to span geography and ethnicity, despite shifts in the proportion of tumors from different molecular subtypes.
A multi-region analysis of medulloblastoma and other tumor types highlighted the dramatic somatic alteration differences that can crop up within a single tumor.
Protein patterns in patient-derived xenografts sometimes pointed to different alterations than those predicted from somatic mutation and expression data.
Researchers used the approach, which analyzes somatic copy number alterations, to identify a targetable pathway, which they then blocked effectively using currently available drugs.
The method allows analysis of copy number at the individual cell level with greater coverage uniformity and more reliable detection than other approaches.
